[HTML][HTML] Leukemic stem cells and therapy resistance in acute myeloid leukemia
P Stelmach, A Trumpp - Haematologica, 2023 - ncbi.nlm.nih.gov
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
[HTML][HTML] Targeting cancer stemness in the clinic: from hype to hope
Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of
genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining …
genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining …
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …
therapies entering clinical translation, yet patient responses remain heterogeneous, and …
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution
A Rodriguez-Meira, R Norfo, S Wen, AL Chédeville… - Nature …, 2023 - nature.com
Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia
Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and
limited treatment options. Here we provide a comprehensive census of the bone marrow …
limited treatment options. Here we provide a comprehensive census of the bone marrow …
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …
[HTML][HTML] Machine learning identifies stemness features associated with oncogenic dedifferentiation
Cancer progression involves the gradual loss of a differentiated phenotype and acquisition
of progenitor and stem-cell-like features. Here, we provide novel stemness indices for …
of progenitor and stem-cell-like features. Here, we provide novel stemness indices for …
Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity
Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex
microenvironment, complicating efforts to understand how different cell types contribute to …
microenvironment, complicating efforts to understand how different cell types contribute to …
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia
stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated …
stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated …
Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia
S Pei, DA Pollyea, A Gustafson, BM Stevens… - Cancer discovery, 2020 - AACR
Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …